Celgene raises 2013 forecast as profit beats estimates

By Bill Berkrot (Reuters) – Celgene Corp raised its earnings forecast for 2013 on Thursday after reporting slightly higher-than-expected quarterly profit on robust sales of its flagship blood cancer drug Revlimid and rapid growth in newer cancer treatments. While Revlimid remains the backbone of the company, Celgene’s newer products are off to an impressive start. Pomalyst, a multiple myeloma drug for patients who have received treatment with at least two prior therapies, had sales of $90 million in its second full quarter on the market, up 35 percent from the prior quarter. …